Fennec Announces $7.6 Million Private Placement of Common Shares Led by venBio Select Advisor RESEARCH TRIANGLE PARK, NORTH CAROLINA — (Marketwired) — 06/08/17 — Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric …
Corvus Pharmaceuticals Completes $75 Million Series B Financing
Funds will Advance Company’s Immuno-Oncology Small Molecule and Antibody Programs Burlingame, CA, September 29, 2015 – Corvus Pharmaceuticals, a private clinical-stage biopharmaceutical company focused on the development of novel agents targeting the immune system to treat patients with cancer, today announced that it closed a $75 million Series B financing. The transaction was led by …
Oncobiologics Secures $31 Million Financing
Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …
Adaptimmune raises $104 mln to develop immune-system cancer drugs
LONDON, Sept 25 (Reuters) – British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells. The Oxford-based private company plans to use the money to advance its programmes to clinical trials against multiple types of cancer, it said on …
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Investor syndicate includes leading biotech and mutual funds. HOUSTON–BUSINESS WIRE–Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T …